Will Curis (CRIS) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/27/21
Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021PRNewsWire • 07/27/21
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromesPRNewsWire • 06/11/21
Curis to Host Virtual Event to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHAPRNewsWire • 06/04/21
Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"PRNewsWire • 06/01/21
Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing EstimatesBenzinga • 05/13/21
Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/13/21
Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Association 2021 Virtual CongressPRNewsWire • 05/12/21
Do Options Traders Know Something About Curis (CRIS) Stock We Don't?Zacks Investment Research • 05/12/21
Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021PRNewsWire • 05/05/21
Will Curis (CRIS) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 05/04/21
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDSPRNewsWire • 04/19/21